FLGT Stock — Fulgent Genetics, Inc.

Fulgent Genetics, Inc. (FLGT)

Updated October 16, 2026.

FLGT is a Stock. Total return is 115.8% over the past 10 years, 200.5 points behind SPY at 316.3%.

Fulgent Genetics operates a clinical diagnostics business providing molecular and genetic testing, anatomic pathology services, and oncology tests to hospitals, medical institutions, insurers, and patients. The company also develops therapeutic candidates for cancer treatment using a targeted nanoencapsulation platform. As an operating company, Fulgent Genetics does not currently have an established distribution schedule.

FLGT performance versus SPY

Price and return data through 2026-10-16.

Total return is 115.8% over the past 10 years, 200.5 points behind SPY at 316.3%. Over the past year its total return — price change plus distributions reinvested — is -13.1%. Its deepest 1-year drawdown was 55.3%.

FLGT key facts

Asset type

Stock

Asset class

Equity

Inception date

09/29/2016

Distribution frequency

None

Last close

$19.81 (as of 2026-10-16)

Market cap

$545,077,954

Average volume

443400.0

Beta

0.933

Payout ratio

0.0%

Forward P/E

7.7042

EPS

$-2.82

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

FLGT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 55.3%.

Who may consider FLGT — and who may not

It is a weaker fit for investors who need monthly cash flow (FLGT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on FLGT

• All tickers starting with F

Tagged: Healthcare.

Frequently asked questions